Cost-effectiveness of CDK4/6 inhibitors

what are cost-benefit ratios of prescibing habitRibociclib, palbociclib and abemaciclib

Real-world and modelled analyses paint a mixed picture: often shows lower per‑patient medical costs versus in claims data, while multiple models conclude that adding palbociclib or to endocrine therap...